Published in final edited form as:

Clin Lung Cancer. 2017 July ; 18(4): e233–e241. doi:10.1016/j.clc.2016.11.002.

Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing among Patients with Newly Diagnosed Metastatic Lung Cancer

Chan Shen^{1,2}, Kenneth L. Kehl³, Bo Zhao¹, George R. Simon⁴, Shouhao Zhou², and Sharon H. Giordano¹

¹Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX

²Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

³Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

⁴Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract

INTRODUCTION—Epidermal Growth Factor Receptor (EGFR)-targeted therapy significantly improves outcomes among patients with non-small cell lung cancer (NSCLC) whose tumors harbor sensitizing mutations. Patterns of EGFR testing have not been well-documented. The objective of this population-based study is to assess the testing pattern on a national scale.

METHODS—Using MarketScan 2012–2014 data, we identified 5842 patients newly diagnosed with metastatic lung cancer from January 2013 to June 2014 and assessed their EGFR mutation testing pattern in the 6 months after diagnosis. We further examined the testing rate among patients who received the EGFR inhibitor erlotinib. Since histology information is not available in this database, we also conducted a subgroup analysis of EGFR testing among patients who were treated with bevacizumab or pemetrexed, who are likely to have nonsquamous NSCLC. Multivariable logistic regression was performed to ascertain factors associated with EGFR testing.

RESULTS—Of 5842 patients with metastatic lung cancer, 1039 (18%) had claims for EGFR testing within 6 months of diagnosis, and 283 (5%) received erlotinib. The testing rate among patients who received erlotinib was 42%. Within a subgroup of 1685 patients treated with bevacizumab or pemetrexed, 616 (37%) underwent EGFR testing. Multivariable logistic regression showed that younger patients, female patients, patients with fewer comorbidities and patients living in the West region were more likely to receive EGFR testing.

Corresponding Author: Chan Shen, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Unit 1444, Houston, TX 77030, Phone: 713.563.0020, Fax: 713.563.0059, cshen@mdanderson.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflicts of Interest: The authors declare no conflicts of interest.

CONCLUSION—This population-based study demonstrates low EGFR testing rates among advanced lung cancer patients in 2013–2014.

Keywords

EGFR testing; newly diagnosed metastatic lung cancer; erlotinib; health services research; MarketScan data

Introduction

In the past decade, substantial advances in molecular and cellular biology have reshaped our understanding of non-small-cell lung cancer (NSCLC). In particular, genotype-based targeted therapies for patients with activating mutations in the epidermal growth factor receptor (EGFR) gene or rearrangements in the anaplastic lymphoma kinase (ALK) or ROS1 genes have improved outcomes significantly for patients with sensitizing mutations.^{1–5}

In 2010, National Comprehensive Cancer Network (NCCN) guidelines included erlotinib as a first-line treatment option for patients with stage IV non-small cell lung cancer harboring activating mutations in EGFR.⁶ In 2011, the American Society of Clinical Oncology (ASCO) published a provisional clinical opinion⁷ recommending EGFR mutation testing for patients with advanced NSCLC, suggesting consideration of EGFR inhibitor therapy as a first-line treatment for patients with EGFR mutations. In 2012, NCCN guidelines recommended that all patients with lung adenocarcinoma be tested for the EGFR mutation.⁸ By early 2013, the standard of care for patients with advanced-stage NSCLC was shifting towards treatment based on a patient's molecular profile.⁹ In July 2013, the College of American Pathologists (CAP)/International Association for the Study of Lung Cancer (IASLC)/Association for Molecular Pathology (AMP) issued a guideline on EGFR testing for patients with advanced lung adenocarcinoma, recommending that physicians use testing for EGFR mutations to guide patient selection for EGFR inhibitor treatment.¹⁰ In October, 2014, ASCO endorsed this guideline.¹¹

The EGFR inhibitors currently on the US market include erlotinib, afatinib and gefitinib. Erlotinib initially received FDA approval in 2004 for second-line treatment of patients with advanced NSCLC. In 2013, erlotinib indications were expanded to include first-line treatment of patients with metastatic NSCLC with EGFR mutations.¹² Afatinib was also approved in July 2013 for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer.¹³ Gefitinib received initial FDA approval in 2003 for the treatment of patients with locally advanced or metastatic NSCLC as a third-line therapy. However, the FDA withdrew that approval in 2005. In July 2015, gefitinib was re-approved as a first-line treatment for metastatic NSCLC patients with EGFR mutations.¹⁴ In November 2015, the FDA granted accelerated approval to osimertinib for patients with T790M resistance mutations in EGFR who have progressed after prior EGFR-targeted therapy.^{15–19}

With such rapid developments in the standard of care, it is critical that oncologists remain up to date on new treatment standards. The literature is scarce on EGFR testing patterns among patients with advanced NSCLC. One study²⁰ investigated testing rates among NSCLC

patients treated in a community-based oncology network and found EGFR testing rates increasing substantially from 2.3% before 2010 to 32% in 2011. However, this study focused on patients receiving second-line treatment, and hence was not directly relevant to the more recent guidelines,¹¹ which recommend EGFR testing at the time of diagnosis. A more recent survey of oncologists conducted between December 2014 and January 2015²¹ demonstrated a self-reported testing rate of 76% for patients with newly diagnosed advanced NSCLC in North America (including the US and Canada). However, studies based on surveys have the fundamental disadvantage of potential reporting bias. Therefore, we conducted a population-based study to assess biomarker testing patterns on a national scale. Our study aims to describe EGFR testing patterns and trends among patients with newly diagnosed advanced non-small cell lung cancer. Further, we aim to identify factors associated with the uptake of EGFR testing.

Method

Data Source

We used the Truven Health MarketScan database, which is a claims-based longitudinal database covering millions of unique patients in the US enrolled in commercial health insurance plans and Medicare supplemental plans. The MarketScan database includes health insurance claims for 50 million employees, spouses, retirees, and their dependents, enrolled in commercial health insurance plans sponsored by over 100 large or medium-sized United States-based employers. The beneficiaries had various types of health care coverage, such as privately insured fee-for-service, point-of-service (POS), or capitated health plans. The health plans include health maintenance organizations (HMOs), preferred provider organizations (PPOs), POS plans, and indemnity plans. The geographical distribution is approximately the same as the US population distribution. These data represent health care across a variety of settings (physician office visits, emergency room visits, inpatient hospital stays, outpatient visits, and outpatient pharmacy claims).²² The MarketScan database is a well-trusted data source for studying treatment patterns. There are a large number of published studies based on MarketScan data in the literature.^{23–26}

Study Cohort

We identified patients diagnosed with new lung cancer from January 2013 to June 2014 via International Classification of Disease 9th Revision (ICD-9) codes 162.0–162.9. Patients were considered to have newly diagnosed lung cancer if they had at least one inpatient claim or two outpatient claims between 30 to 180 days apart and did not have any other lung cancer claims within the 6 months prior to the first one during the time period between January 2013 and June 2014. We defined the first lung cancer claim in 2013 as the diagnosis date and excluded patients without continuous enrollment 6 months prior to and 6 months after the diagnosis date in order to ensure that we captured patients with data on all relevant claims around the time of diagnosis. In order to restrict the cohort to patients with recurrent or metastatic disease, we excluded patients with a claim for lung cancer surgery. The Current Procedural Terminology (CPT) codes used to identify surgical treatment included: 32440, 32442, 32445, 32480, 32482, 32484, 32486, 32488, 32500, 32503, 32504, 32520, 32522, 32525, 32657, and 32663. The list was established in a published study.²⁷ We did not

include codes that indicate surgical biopsy (e.g., 32405, 32096, 77012). It is unlikely that providers would downcode a lung surgery procedure as a surgical biopsy, since the reimbursement amount would depend on the coding. We further restricted the cohort to patients who had ICD-9 codes indicating secondary malignant neoplasms to specific other sites (197.4–198.7, 198.81, 198.82) within 6 months of diagnosis. These secondary malignancy codes were first proposed by Lamont and colleagues²⁸ for breast cancer patients and further validated for determination of recurrent disease among several types of cancer, including lung cancer, by Hassett et al.²⁹ We modified the secondary malignancy codes list used in this study by further excluding secondary malignant neoplasm of mediastinum, pleura and respiratory organs (197.1–197.3) and secondary malignant neoplasm of other specified sites (198.89), in order to create a specific cohort of patients with metastatic lung cancer. Our inclusion and exclusion criteria are detailed in the Supplementary Figure.

Key Variables

Our first key outcome variable was whether or not EGFR testing was performed for a given patient. We identified EGFR testing using CPT code 81235 (EGFR gene analysis, common variants, nonspecific to methodology of testing). This specific code for EGFR testing was new in 2013; before January 2013, there was no specific code for EGFR testing, and claims for EGFR testing usually included several non-specific CPT codes. We focused on lung cancer patients identified from January 2013 to June 2014 to ensure a 6 month follow-up window. While it is possible that patients may have received multi-plex testing, there was no CPT code for multi-plex testing during the timeframe of our study cohort. As providers are reimbursed based on the medical claims, we expect that most providers would use the EGFR testing billing code to ensure proper reimbursement.

Our second key outcome variable was filled prescriptions for erlotinib, which was the only FDA approved EGFR inhibitor covering the whole study period. We captured the use of erlotinib by National Drug Codes (NDCs): 50242-0062-01, 50242-0063-01, 50242-0064-01, 54868-5290-00, 54868-5447-00 and 54868-5474-00.

Explanatory Variables

We conducted multivariable analyses to examine the factors associated with the uptake of EGFR testing. We included patient demographics, comorbidity scores, a binary variable (yes/no) indicating radiation therapy, and type of insurance. The demographic information included age (18–54, 55–64, 65–74, ≥75), gender (male vs female), and region (Northeast, North Central, West, South). We used the Deyo-Romano modified Charlson comorbidity score, which is a commonly adopted measure for ascertainment of comorbidity in studies using claims data.^{30–33} The comorbidity score was derived from Medicare Provider Analysis and Review, Outpatient and Carriers claims files during the 6 months preceding diagnosis and categorized into three groups: zero, one, or at least two. We captured whether a patient received radiation within 6 months of diagnosis based on CPT codes (77371–77373, 77401–77525, 77761–77799, G0174, G0251, G0339, G0340). We categorized type of insurance into four groups: Preferred Provider Organization (PPO), Health Maintenance Organization (HMO), Point of Service (POS), and other. To examine the time trend, we also included a

categorical variable for time of diagnosis: first half of year 2013, second half of year 2013, and first half of year 2014.

Analyses

We described the percentage of patients receiving EGFR mutation testing by quarter in order to evaluate for a trend in testing rates. Group differences in the use of EGFR testing were tested with chi-squared statistics. We also used multivariate logistic regression to explore factors associated with EGFR testing, and we present findings as adjusted odds ratios (ORs) and their corresponding 95% confidence intervals (CIs).

One limitation of the MarketScan database is that it does not provide histology information. Therefore, a cohort defined by billing claims may include patients with lung cancer histologies that would not merit EGFR testing (including squamous cell and small cell carcinoma). We therefore conducted a subgroup analysis to address this issue. In the subgroup analysis, we focused on the patients who were treated with bevacizumab, pemetrexed, or both within the 6 months after diagnosis. This group should be highly enriched for patients with non-squamous, non-small cell lung cancer, since these two drugs are almost exclusively used for patients with non-squamous histology, and they would not be indicated for small cell lung cancer.^{34–37}

It is possible that some patients received EGFR testing more than 6 months after diagnosis. For sensitivity analyses, we therefore released the 6 month time window restriction and included all EGFR testing captured at any time point in 2013–2014. We then examined the timing of EGFR testing relative to diagnosis. In case some claims for EGFR mutation testing were submitted using the nonspecific 2012 CPT codes instead of the new 2013 codes, we conducted another sensitivity analysis considering a 2012 molecular pathology CPT code (83912: interpretation and report) adopted by Mayo Clinic and two insurance companies.^{38–40}

All statistical analyses were conducted in SAS 9.3 (SAS Institute, Cary NC). The Institutional Review Board at The University of Texas MD Anderson Cancer Center exempted this study from review because all patients in the database had been de-identified.

Results

Characteristics of the study cohort are provided in Table 1. Of 5842 metastatic lung cancer patients, 1039 (18%) had a claim for EGFR testing within 6 months of diagnosis. We found that 283 (5%) received erlotinib treatment. Notably, 163 (58%) of the patients who received erlotinib did not have EGFR testing.

Of the 5842 patients, 1685 (29%) were treated with bevacizumab or pemetrexed within 6 months of diagnosis. Within this group of patients likely to have non-squamous, non-small cell lung cancer, 616 (37%) had EGFR testing; among patients treated with erlotinib, 43% did not have EGFR testing.

In unadjusted analyses of the whole cohort, the EGFR testing rate was lower among older patients, patients living in the North Central region, patients with higher comorbidity scores,

and patients who did not receive radiation therapy (Table 1). Within the smaller subgroup of patients treated with bevacizumab or pemetrexed, the result was similar except that males had a significantly lower EGFR testing rate, and there were no statistically significant differences by region. In both the whole cohort and the subgroup, we observed an upward trend in the uptake of EGFR testing. In the whole cohort, the testing rate increased from 16% in the first half of 2013 to 20% in the first half of 2014. In the subgroup with bevacizumab or pemetrexed, the testing rate increased from 32% to 41%.

In multivariable logistic regression models conducted on the whole cohort, age was strongly associated with EGFR testing. Younger patients (18–54 years old) were more likely to receive EGFR testing compared with those aged 65–74 with an OR of 1.79 (95% CI: 1.45–2.22). We also found a significant associations between comorbidity scores, region and testing rate; however, in the subgroup analysis restricted to patients treated with bevacizumab or pemetrexed, region and comorbidity score were no longer significant predictors. In this subgroup, we found that female patients were significantly more likely to have testing (OR 1.23, 95% CI 1.01–1.51). In both the whole cohort and the subgroup analysis, testing rates were significantly higher in the first half of 2014 compared to the first half of 2013. Detailed results are provided in Table 2.

Figure 1a describes the percentage of metastatic lung cancer patients that received EGFR testing by quarter of diagnosis. We observed a gradual increasing time trend in the rates of EGFR testing throughout our study period, though rates remained below 25% (ranging from 16% to 21%) in every quarter that we studied. The testing rate was consistently much higher among patients who received erlotinib treatment, but it was still never above 50% in the overall cohort. Among patients who received bevacizumab or pemetrexed, rates of EGFR testing were consistently higher, but remained under 45% across quarters of diagnosis (Figure 1b). The increase in the rate of testing with time was more pronounced within this subgroup, growing from 31% to 43%.

In sensitivity analyses, we included EGFR testing captured after 6 months following diagnosis. By releasing the 6 month restriction, we added 85 patients with testing, which was 7.3% of all patients who received EGFR testing at any time point of the year. We also examined the time from diagnosis to EGFR testing. The mean time until testing was 40 days (standard deviation=90 days); median time was 9 days (interquartile range=36 days). Therefore, a 6 month window from diagnosis was likely to be sufficient to capture most EGFR testing.

We found that only 4 patients in our cohort had the discontinued nonspecific 2012 molecular pathology CPT code in 2013–2014. It is not clear whether these codes represented EGFR testing or some other molecular test. However, the low rate implies that most practices adopted the new CPT codes promptly, such that the new CPT codes should not have failed to identify many patients who had EGFR testing.

Discussion

Our study provides a population-based view of the rates of EGFR testing among patients with newly diagnosed advanced lung cancer from January 2013 to June 2014. We found that less than 25% of patients with newly diagnosed metastatic NSCLC received EGFR testing within 6 months of diagnosis. We additionally assessed rates of EGFR testing among the subgroup of patients who received erlotinib and found that only 42% of patients who were prescribed erlotinib within 6 months of diagnosis had testing for an EGFR mutation. Although erlotinib is FDA-approved both as first-line therapy for patients with EGFR mutation-positive NSCLC and as maintenance therapy and second-line therapy without regard to EGFR mutation status,⁴¹ the efficacy of EGFR inhibitors is greater among patients who harbor EGFR mutations.^{42, 43} When we restricted the sample to patients treated with bevacizumab or pemetrexed, the vast majority of whom likely had non-squamous NSCLC, we observed a higher testing rate of 37%. Nevertheless, this testing rate is low, considering the clinical benefits of erlotinib among patients with EGFR mutated non-small cell lung cancer.

We also found that older patients were less likely to receive testing in both the whole study cohort and the subgroup treated with bevacizumab and pemetrexed. It is possible that older patients were more likely to have extensive smoking histories, and therefore to have squamous or small cell lung cancer that did not warrant EGFR testing. Additionally, elderly or very ill patients may have been less likely to pursue cancer-directed therapy at all, and in those cases, EGFR mutation testing might not have been performed.

On the other hand, the association between female sex and EGFR testing was stronger in the subgroup of patients treated with bevacizumab or pemetrexed. Female patients with lung adenocarcinoma are more likely to harbor sensitizing EGFR mutations.^{44–46} It is possible that physicians were aware of the higher prevalence of EGFR mutations among women and therefore performed EGFR testing more often for female patients. However, since these patients largely had non-squamous NSCLC, for which EGFR testing is now recommended, this disparity was likely not clinically appropriate.

Our results emphasize the need to promote rapid dissemination of medical advances among physicians. Indeed, our study analyzed patients diagnosed with metastatic lung cancer from January 2013 to June 2014. By the beginning of that time period, erlotinib had been listed as an option for first-line treatment in NCCN guidelines for three years,⁶ ASCO's provisional clinical opinion recommending EGFR mutation analysis for patients considering first-line EGFR-targeted therapy had been available for two years,⁷ and NCCN guidelines had recommended EGFR mutation testing for all patients with lung adenocarcinoma in the previous year. Results of the IPASS trial, demonstrating a significant progression-free survival advantage for gefitinib over chemotherapy in the first-line setting, were published four years prior.¹ Our study showed a modest pace of increase in testing rate with time; however, it is still possible that uptake of EGFR testing in the community has further increased at a faster pace since our study period, and further research should assess subsequent testing rates.

This study has several limitations. First, the ICD-9 codes we used to determine our cohort were able to define cancer site, but did not directly contain information regarding cancer histology. Therefore, the rate of EGFR testing may be higher among a more selected group of patients with advanced non-squamous NSCLC. It has been estimated that approximately 40% of lung cancers are adenocarcinomas.⁴⁷ We also used SEER*Stat software (version 8.3.2; Surveillance Research Program, National Cancer Institute, Bethesda, MD) and found that approximately 36% of metastatic lung/bronchus cancer patients had adenocarcinoma histology. If we assumed that 35% to 40% of our cohort had adenocarcinomas, and that EGFR testing occurred only within that subgroup, our EGFR testing rate would have been 44%–51%, still indicating that a large proportion of potentially eligible patients did not receive EGFR testing. Indeed, our analysis of the subgroup treated with bevacizumab and/or pemetrexed was in line with the above observation; we found a 37% testing rate among this subgroup. It is important to note that not all patients with metastatic adenocarcinomas would receive bevacizumab and/or pemetrexed. Our sample showed that only 29% of the metastatic lung cancer patients received bevacizumab and/or pemetrexed, which is lower than our expected percentage with adenocarcinoma histology (35%–40%). The literature shows that the rate of guideline adherence of first-line therapy for advanced and metastatic disease in NSCLC patients is relatively good at 75% (compared to 61% for adjuvant therapy among early-stage disease) in US community oncology practices.⁴⁸ Another study found the rate among medically fit patients with stages II–IV NSCLC was 71%.⁴⁹ Further, it is possible that patients received erlotinib as first-line treatment and were not included in the subgroup. We conducted both whole group analysis including all newly diagnosed metastatic lung cancer patients and a subgroup analysis for patients treated with bevacizumab and/or pemetrexed. We expect that the whole group is probably sensitive but not specific, the subgroup is probably specific but not sensitive, in terms of capturing NSCLC patients with adenocarcinoma histology.

Additionally, it is possible that some patients did not receive EGFR mutation testing due to lack of tissue to submit for molecular analyses. Our observational study based on claims data does not provide information on the availability of tissue for testing. Additionally, patients who participated in clinical trials and had EGFR testing performed according to a study protocol, rather than billed to insurance, would not have been captured using claims data. However, since 5% or less of adults with cancer in the US participate in clinical trials,^{50–54} underestimation of testing for this reason was likely not substantial.

Our data do not include information on whether patients were treated at community-based hospitals and academic medical centers. It is possible that the testing rate at community-based hospitals and academic medical centers are different. However, we do not have information on the proportion of community-based hospitals and academic medical centers included in the database. It would also be interesting to study the first, second and third line treatments of metastatic lung cancer patients. However it is challenging to use claims data to identify the line of therapy. One important paper in the literature developed an algorithm to identify first-, second-, and third-line chemotherapy among lung cancer patients.⁵⁵ The algorithm requires that patients have at least three chemotherapy claims to ascertain the first-line therapy and then at least 28 days following the last delivery date of a different first-line chemotherapy to ascertain the second-line therapy. They found that the mean interval

between the last date of administration of the first-line agent and the initiation of the second-line treatment was 114 days for injectable agents. In our study, the follow-up time is only 6 month, which hinders the study of first, second and third line therapies for the patients.

Our study is one of the few papers in the literature to report the uptake of EGFR testing among patients with advanced lung cancer from a population perspective. Another study examined 1358 patients diagnosed in 2010 with histologically-confirmed NSCLC from the SEER data and found that the rate of EGFR testing was 17% overall and 23% for stage IV patients.⁵⁶ Our study identified 5842 patients newly diagnosed with metastatic lung cancer from January 2013 to June 2014 from MarketScan data and found that the rate of EGFR testing was 18% overall and 37% among a subgroup treated with bevacizumab and/or pemetrexed who are likely to have non-squamous NSCLC. Although the results from the two studies cannot be compared directly, they are reasonably in line with each other. The overall rate in our study would include patients with small cell lung cancer, who would be less likely to receive EGFR testing; therefore we expect the testing rate among metastatic NSCLC patients overall to be higher than 18%. If we assume that 80% of the lung cancer patients have NSCLC⁴⁷ and none of the SCLC patients received EGFR testing, then this calculation implies a 23% testing rate in metastatic NSCLC, which is the same as in the study based on SEER data.

Further research should examine the uptake of testing for other molecular biomarkers such as the ALK and ROS1 rearrangements, as well as identify specific barriers to the dissemination of novel evidence-based testing and therapy. Some other interesting future research directions include studying the adoption of first, second and third line treatments and examining the potential disparities in the adoption of EGFR testing by community-based and academic medical centers.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding: This study is funded in part by L.E. and Virginia Simmons Fellow fund at Rice University's Baker Institute Center for Health and Biosciences, the Duncan Family Institute, and CPRIT RP140020-P2.

References

1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med*. 2009; 361:947–957. [PubMed: 19692680]
2. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). *J Clin Oncol*. 2011; 29:2866–2874. [PubMed: 21670455]
3. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol*. 2011; 12:735–742. [PubMed: 21783417]

4. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med*. 2014; 371:2167–2177. [PubMed: 25470694]
5. Bergethson K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. *J Clin Oncol*. 2012; 30:863–870. [PubMed: 22215748]
6. Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. *J Natl Compr Canc Netw*. 2010; 8:740–801. [PubMed: 20679538]
7. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. *J Clin Oncol*. 2011; 29:2121–2127. [PubMed: 21482992]
8. Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer. *J Natl Compr Canc Netw*. 2012; 10:1236–1271. [PubMed: 23054877]
9. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. *J Clin Oncol*. 2013; 31:1039–1049. [PubMed: 23401433]
10. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *J Mol Diagn*. 2013; 15:415–453. [PubMed: 23562183]
11. Leigh NB, Rekhman N, Biermann WA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. *J Clin Oncol*. 2014; 32:3673–3679. [PubMed: 25311215]
12. Office Director Memo, Application Number:201292Orig1s000. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201292Orig1s000ODMemo.pdf
13. Administration USFaD. Prescribing information: Afatinib Center for Drug Evaluation and Research. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/201292s000lbl.pdf
14. US Food and Drug Administration(FDA). <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm454678.htm>
15. Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. *Clin Cancer Res*. 2006; 12:5764–5769. [PubMed: 17020982]
16. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. *Clin Cancer Res*. 2006; 12:6494–6501. [PubMed: 17085664]
17. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med*. 2005; 352:786–792. [PubMed: 15728811]
18. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med*. 2005; 2:e73. [PubMed: 15737014]
19. US Food and Drug Administration(FDA). <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm>
20. Pan IW, Mallick R, Dhanda R, Nadler E. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network. *Lung Cancer*. 2013; 82:469–476. [PubMed: 24396885]
21. Spicer J, BT, Peters M. EGFR mutation testing and oncologist treatment hchoice in advanced NSCLC: global trends and differences. *Ann Onc*. 2015; 26:i60.
22. Hansen, LGCS. Health research data for the real world: the MarketScan databases. Ann Arbor, MI: Truven Health Analytics; 2011. White Paper.
23. Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. *Cancer Med*. 2016; 5:182–191. [PubMed: 26710718]

24. Neugut AI, Zhong X, Wright JD, Accordini M, Yang J, Hershman DL. Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer. *JAMA Oncol.* 2016
25. Roberts MC, Dusetzina SB. Use and Costs for Tumor Gene Expression Profiling Panels in the Management of Breast Cancer From 2006 to 2012: Implications for Genomic Test Adoption Among Private Payers. *J Oncol Pract.* 2015; 11:273–277. [PubMed: 26105668]
26. Zhao Z, Wang S, Barber BL. Treatment patterns in patients with metastatic melanoma: a retrospective analysis. *J Skin Cancer.* 2014; 2014:371326. [PubMed: 24883209]
27. Simpson DR, Martinez ME, Gupta S, et al. Racial disparity in consultation, treatment, and the impact on survival in metastatic colorectal cancer. *J Natl Cancer Inst.* 2013; 105:1814–1820. [PubMed: 24231453]
28. Lamont EB, Herndon JE 2nd, Weeks JC, et al. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). *J Natl Cancer Inst.* 2006; 98:1335–1338. [PubMed: 16985253]
29. Hassett MJ, Ritzwoller DP, Taback N, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. *Med Care.* 2014; 52:e65–73. [PubMed: 23222531]
30. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987; 40:373–383. [PubMed: 3558716]
31. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol.* 1992; 45:613–619. [PubMed: 1607900]
32. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. *J Clin Epidemiol.* 1993; 46:1075–1079. [PubMed: 8410092]
33. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. *J Clin Epidemiol.* 2000; 53:1258–1267. [PubMed: 11146273]
34. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. *J Clin Oncol.* 2004; 22:2184–2191. [PubMed: 15169807]
35. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. *Oncologist.* 2009; 14:253–263. [PubMed: 19221167]
36. Ettinger DS, Wood DE, Akerley W, et al. Non-Small Cell Lung Cancer, Version 6.2015. *J Natl Compr Canc Netw.* 2015; 13:515–524. [PubMed: 25964637]
37. Kalemkerian GP, Akerley W, Bogner P, et al. Small cell lung cancer. *J Natl Compr Canc Netw.* 2013; 11:78–98. [PubMed: 23307984]
38. First Carolina care. [http://www.firstcarolinacare.com/providers/Policies/Medical%20Policies/2.04.34%20Epidermal%20Growth%20Factor%20Receptor%20\(EGFR\)%20Mutation%20Analysis%20for%20Patients%20with%20Non-Small%20Cell%20Lung%20Cancer%20\(NSCLC\).pdf](http://www.firstcarolinacare.com/providers/Policies/Medical%20Policies/2.04.34%20Epidermal%20Growth%20Factor%20Receptor%20(EGFR)%20Mutation%20Analysis%20for%20Patients%20with%20Non-Small%20Cell%20Lung%20Cancer%20(NSCLC).pdf)
39. Clinic M. <http://www.mayomedicallaboratories.com/test-updates/attachment.php?id=22590>
40. Shield BCB. https://www.bcbsnc.com/assets/services/public/pdfs/medicalpolicy/epidermal_growth_factor_receptor_mutation_analysis.pdf
41. US Food and Drug administration (FDA). <http://www.cancer.gov/about-cancer/treatment/drugs/fda-erlotinib-hydrochloride>
42. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science.* 2004; 304:1497–1500. [PubMed: 15118125]
43. Gridelli C, Ciardiello F, Gallo C, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. *J Clin Oncol.* 2012; 30:3002–3011. [PubMed: 22778317]
44. Mariano C, Bosdet I, Karsan A, et al. A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-

- small cell lung cancer patients with advanced disease. *Lung Cancer*. 2014; 83:73–77. [PubMed: 24192511]
45. Ontario HQ. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. *Ont Health Technol Assess Ser*. 2010; 10:1–48.
 46. Szumera-Cieckiewicz A, Olszewski WT, Tysarowski A, et al. EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. *Int J Clin Exp Pathol*. 2013; 6:2800–2812. [PubMed: 24294366]
 47. American Cancer Society (ACS). <http://www.cancer.org/acs/groups/cid/documents/webcontent/003115-pdf.pdf>
 48. Wang Z, Askamit I, Tuscher L, Bergstrom K. Rates of guideline adherence among US community oncologists treating NSCLC. *Am J Manag Care*. 2013; 19:185–192. [PubMed: 23544766]
 49. Salloum RG, Smith TJ, Jensen GA, Lafata JE. Factors associated with adherence to chemotherapy guidelines in patients with non-small cell lung cancer. *Lung Cancer*. 2012; 75:255–260. [PubMed: 21816502]
 50. Nass, SJ.Moses, HL., Mendelsohn, J., editors. Institute of Medicine Committee on Cancer Clinical T, the NCICGP. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Washington (DC): National Academies Press (US); Copyright 2010 by the National Academy of Sciences. All rights reserved., 2010
 51. Fouad MN, Lee JY, Catalano PJ, et al. Enrollment of patients with lung and colorectal cancers onto clinical trials. *J Oncol Pract*. 2013; 9:e40–47. [PubMed: 23814523]
 52. Kehl KL, Arora NK, Schrag D, et al. Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer. *J Natl Cancer Inst*. 2014; 106
 53. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. *JAMA*. 2004; 291:2720–2726. [PubMed: 15187053]
 54. Stewart JH, Bertoni AG, Staten JL, Levine EA, Gross CP. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. *Ann Surg Oncol*. 2007; 14:3328–3334. [PubMed: 17682824]
 55. Ramsey SD, Martins RG, Blough DK, Tock LS, Lubeck D, Reyes CM. Second-line and third-line chemotherapy for lung cancer: use and cost. *Am J Manag Care*. 2008; 14:297–306. [PubMed: 18471034]
 56. Enewold L, Thomas A. Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States. *PLoS One*. 2016; 11:e0156728. [PubMed: 27294665]

a **b** **Figure 1.**

a: Rate of EGFR testing among patients by quarter of diagnosis in 2013 and 2014

b: Rate of EGFR testing by quarter of diagnosis in 2013 and 2014 among patients treated with bevacizumab and/or pemetrexed

Table 1

Patient characteristics and EGFR mutation testing rates

Covariates	Whole cohort			Subgroup treated with bev or pem		
	EGFR testing performed	No EGFR testing performed	P	EGFR testing performed	No EGFR testing performed	P
All	1039 (17.79%)	4803 (82.21%)		616 (36.56%)	1069 (63.44%)	
Treated with Erlotinib			<.001			<.001
No	919 (16.53%)	4640 (83.47%)		562 (35.32%)	1029 (64.68%)	
Yes	120 (42.40%)	163 (57.60%)		54 (57.45%)	40 (42.55%)	
Age			<.001			<.001
18–54	252 (25.02%)	755 (74.98%)		148 (41.93%)	205 (58.07%)	
55–64	457 (21.27%)	1692 (78.73%)		285 (40.89%)	412 (59.11%)	
65–74	208 (14.15%)	1262 (85.85%)		120 (30.46%)	274 (69.54%)	
75+	122 (10.03%)	1094 (89.97%)		63 (26.14%)	178 (73.86%)	
Sex			0.126			0.024
Female	539 (18.55%)	2366 (81.45%)		332 (39.20%)	515 (60.80%)	
Male	500 (17.02%)	2437 (82.98%)		284 (33.89%)	554 (66.11%)	
Region			0.009			0.618
North Central	291 (15.99%)	1529 (84.01%)		193 (36.83%)	331 (63.17%)	
Northeast	248 (18.86%)	1067 (81.14%)		137 (39.26%)	212 (60.74%)	
South	305 (17.20%)	1468 (82.80%)		187 (34.95%)	348 (65.05%)	
West	195 (20.88%)	739 (79.12%)		99 (35.74%)	178 (64.26%)	
Comorbidity Score			<.001			0.015
0	491 (21.16%)	1829 (78.84%)		306 (39.90%)	461 (60.10%)	
1	338 (17.41%)	1603 (82.59%)		199 (35.41%)	363 (64.59%)	
2+	210 (13.28%)	1371 (86.72%)		111 (31.18%)	245 (68.82%)	
Radiation Therapy			<.001			0.009
No	316 (13.49%)	2026 (86.51%)		207 (32.60%)	428 (67.40%)	
Yes	723 (20.66%)	2777 (79.34%)		409 (38.95%)	641 (61.05%)	
Insurance			<.001			0.037
HMO	97 (17.29%)	464 (82.71%)		58 (36.48%)	101 (63.52%)	
POS	69 (20.72%)	264 (79.28%)		35 (40.23%)	52 (59.77%)	

Covariates	Whole cohort			Subgroup treated with bev or pem		
	EGFR testing performed	No EGFR testing performed	P	EGFR testing performed	No EGFR testing performed	P
PPO	600 (19.69%)	2448 (80.31%)		363 (38.99%)	568 (61.01%)	
Other	273 (14.37%)	1627 (85.63%)		160 (31.50%)	348 (68.50%)	
Time of diagnosis			0.013			0.008
2013 first half	316 (15.99%)	1660 (84.01%)		186 (32.46%)	387 (67.54%)	
2013 second half	359 (17.83%)	1654 (82.17%)		211 (36.13%)	373 (63.87%)	
2014 first half	364 (19.64%)	1489 (80.36%)		219 (41.48%)	309 (58.52%)	

* bev: bevacizumab; pem: pemetrexed

*PPO: Preferred Provider Organization plan; HMO: Health Maintenance Organization plan; POS: Point of Service plan

Table 2

Multivariable logistic model for EGFR mutation testing

Covariates	Whole cohort			Subgroup treated with bev or pem		
	OR	CI	P	OR	CI	P
Age						
18–54	1.79	(1.45, 2.22)	<.001	1.45	(1.06, 1.99)	0.019
55–64	1.50	(1.25, 1.81)	<.001	1.44	(1.10, 1.90)	0.008
65–74	Reference			Reference		
75+	0.74	(0.58, 0.94)	0.015	0.86	(0.60, 1.24)	0.431
Sex						
Male	Reference			Reference		
Female	1.07	(0.93, 1.23)	0.33	1.23	(1.01, 1.51)	0.045
Region						
North Central	Reference			Reference		
Northeast	1.13	(0.93, 1.37)	0.226	1.06	(0.79, 1.41)	0.697
South	0.97	(0.81, 1.16)	0.727	0.83	(0.64, 1.08)	0.171
West	1.36	(1.10, 1.67)	0.004	0.93	(0.68, 1.27)	0.636
Comorbidity Score						
0	Reference			Reference		
1	0.86	(0.73, 1.00)	0.052	0.86	(0.68, 1.08)	0.187
2+	0.73	(0.60, 0.87)	<.001	0.82	(0.62, 1.09)	0.179
Radiation Therapy						
No	Reference			Reference		
Yes	1.58	(1.36, 1.83)	<.001	1.23	(1.00, 1.53)	0.054
Insurance						
HMO	0.90	(0.71, 1.15)	0.411	0.97	(0.68, 1.38)	0.846
POS	1.10	(0.82, 1.46)	0.534	1.02	(0.65, 1.62)	0.917
PPO	Reference			Reference		
Other	0.85	(0.72, 1.00)	0.055	0.79	(0.62, 1.01)	0.056
Time of diagnosis						
2013 first half	Reference			Reference		

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Covariates	Whole cohort			Subgroup treated with bev or pem		
	OR	CI	P	OR	CI	P
2013 second half	1.11	(0.93, 1.31)	0.246	1.13	(0.88, 1.44)	0.348
2014 first half	1.25	(1.05, 1.48)	0.01	1.47	(1.14, 1.89)	0.003

* bev: bevacizumab; pem: pemetrexed

*PPO: Preferred Provider Organization plan; HMO: Health Maintenance Organization plan; POS: Point of Service plan